GLP-1

Semaglutide (Ozempic & Wegovy): Complete Guide to Dosing, Weight Loss, and Side Effects

Medici

30 Apr 2026 — 7 min read

Semaglutide has reshaped modern medicine. From controlling blood sugar in people with type 2 diabetes to producing dramatic weight loss in people with obesity, this once-weekly injectable—and now pill—has become one of the most prescribed medications in the world. Sold under the brand names Ozempic, Wegovy, and Rybelsus, semaglutide belongs to a class of drugs called GLP-1 receptor agonists that mimic a natural gut hormone to regulate appetite, blood sugar, and metabolism.

This guide covers everything you need to know: how semaglutide works at the molecular level, its dosing schedules for both diabetes and weight loss, what clinical trials show about outcomes, its safety profile, and how it compares head-to-head against tirzepatide (Mounjaro/Zepbound).

What Is Semaglutide?

Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a hormone naturally released by the gut after eating. It was developed by Novo Nordisk and first approved by the FDA in 2017 for type 2 diabetes management under the brand name Ozempic. In 2021, a higher-dose formulation (2.4 mg) was approved for chronic weight management under the brand name Wegovy.

What makes semaglutide unique among GLP-1 receptor agonists is its exceptionally long half-life—approximately one week. This is achieved through structural modifications that enable tight albumin binding and resistance to enzymatic degradation, allowing for once-weekly dosing rather than daily injections required by older GLP-1 drugs like liraglutide.

A third formulation, Rybelsus, delivers semaglutide orally (3–14 mg daily) for type 2 diabetes. And in early 2026, the FDA approved the Wegovy pill—oral semaglutide 25 mg taken once daily—making semaglutide the first oral GLP-1 approved specifically for weight loss.

How Semaglutide Works: Mechanism of Action

Semaglutide binds to and activates GLP-1 receptors throughout the body. Its effects operate on multiple systems simultaneously.

Central Effects: Brain and Appetite Regulation

GLP-1 receptors in the hypothalamus and brainstem regulate appetite. Semaglutide directly stimulates appetite-suppressing neurons (POMC/CART neurons) while inhibiting appetite-stimulating neurons (NPY/AgRP neurons). The result is a powerful and sustained reduction in hunger, food cravings, and calorie intake. Many patients on semaglutide report losing interest in food—a phenomenon researchers call "food noise" suppression.

Pancreatic Effects: Blood Sugar Control

Semaglutide stimulates glucose-dependent insulin secretion—meaning it triggers insulin release only when blood glucose is elevated. This makes it highly effective for blood sugar control without the hypoglycemia risk associated with older diabetes drugs like sulfonylureas. It also suppresses glucagon release, further reducing postprandial glucose spikes.

Gastrointestinal Effects: Gastric Slowing

Semaglutide slows gastric emptying, meaning food moves through the stomach more slowly. This prolongs satiety, blunts post-meal glucose spikes, and reduces overall caloric intake. The gastric slowing effect is also responsible for the most common side effects: nausea, particularly during dose escalation.

Cardiovascular Effects

Beyond metabolic control, semaglutide has demonstrated direct anti-inflammatory and cardioprotective effects, reducing atherosclerosis progression and lowering markers of systemic inflammation. These extend its clinical benefits well beyond glucose and weight management.

FDA-Approved Forms and Indications

Semaglutide is currently available in four formulations:

Ozempic (injectable, weekly): Type 2 diabetes management and cardiovascular risk reduction. Maximum dose 2 mg/week.
Wegovy (injectable, weekly): Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity. Maximum dose 2.4 mg/week.
Wegovy pill (oral, daily): FDA-approved in early 2026 for chronic weight management—the first oral GLP-1 approved specifically for obesity. Doses: 1.5 mg, 4 mg, 9 mg, 25 mg.
Rybelsus (oral, daily): Type 2 diabetes. Doses range from 3–14 mg daily.

Dosing and Titration Schedules

Semaglutide is always started at a low dose and escalated gradually over months. The slow titration is essential—it allows the body to adapt and dramatically reduces the severity of gastrointestinal side effects. Never skip titration steps.

Ozempic Dosing (Type 2 Diabetes)

Weeks 1–4: 0.25 mg once weekly (starter dose; not therapeutically effective at this level)
Weeks 5–8: 0.5 mg once weekly
Week 9 onward: 1 mg once weekly (standard maintenance)
Optional escalation: Up to 2 mg weekly if additional glycemic control is needed after at least 4 weeks at 1 mg

Wegovy Dosing (Injectable Weight Management)

Weeks 1–4: 0.25 mg once weekly
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1.0 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Week 17 onward: 2.4 mg once weekly (maintenance dose)

Injections are given subcutaneously (under the skin) in the abdomen, thigh, or upper arm. Rotate injection sites weekly. Semaglutide can be injected at any time of day, with or without food, on the same day each week.

Wegovy Pill (Oral, Daily)

The oral Wegovy must be taken on an empty stomach with up to 4 oz of plain water. Patients must wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. The titration moves through 1.5 mg → 4 mg → 9 mg → 25 mg over approximately 16 weeks.

Clinical Trial Outcomes: What the Data Shows

STEP 1 — The Landmark Weight Loss Trial

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity (no diabetes) and randomized them to weekly injectable semaglutide 2.4 mg or placebo for 68 weeks. Key results:

Mean weight loss: 14.9% of body weight with semaglutide vs. 2.4% with placebo
86% of participants achieved at least 5% weight loss
50% achieved at least 15% weight loss
32% achieved at least 20% weight loss

These results were unprecedented for a non-surgical weight loss intervention at the time of publication.

STEP UP — Higher Dose, Higher Outcomes

Phase IIIb data presented at the 2025 ADA Scientific Sessions showed that an investigational 7.2 mg dose of injectable semaglutide produced a mean weight loss of 21% at 68 weeks in adults with obesity. Over 90% of participants achieved at least 5% weight loss, and one-third lost 25% or more. This confirmed what researchers suspected: semaglutide's efficacy is strongly dose-dependent, and higher doses may eventually reach the territory of bariatric surgery outcomes.

OASIS 4 — Oral Semaglutide for Weight Loss

The OASIS 4 trial evaluated oral semaglutide 25 mg daily (the Wegovy pill) in adults with obesity or overweight with comorbidities. In adherent participants, mean weight loss was 16.6%, with one-third achieving at least 20% weight loss. Serious adverse events were actually less frequent with oral semaglutide (3.9%) than placebo (8.8%).

SELECT — Cardiovascular Risk Reduction

The SELECT trial was a watershed moment for semaglutide. In 17,604 adults with overweight or obesity, established cardiovascular disease, but no diabetes, weekly Wegovy 2.4 mg reduced major adverse cardiovascular events (MACE: heart attack, stroke, cardiovascular death) by 20% compared to placebo over approximately 3.3 years. This led to FDA approval of Wegovy specifically for cardiovascular risk reduction in 2024—a historic expansion of its indications beyond weight loss.

Side Effects and Safety Profile

Common Side Effects

Gastrointestinal effects are the most frequently reported side effects, affecting the majority of patients to some degree. These are largely a consequence of slowed gastric emptying:

Nausea: Reported in approximately 44% of participants in weight loss trials. Typically mild-to-moderate and time-limited, most pronounced during dose escalation, and tends to diminish over 2–4 weeks at each dose level.
Vomiting: Less common than nausea; typically resolves with continued treatment
Diarrhea and constipation
Abdominal pain and bloating
Injection site reactions (for injectable forms)

Managing GI Side Effects

Most gastrointestinal side effects can be minimized by following a few simple strategies:

Never skip titration steps—the slow dose escalation is the most effective tool for tolerability
Eat smaller meals and reduce high-fat foods, especially during the first weeks of each new dose
Avoid carbonated beverages and eat slowly
Stay well hydrated
If nausea is severe, speak with your provider—dose delays are sometimes appropriate

Black Box Warning: Thyroid C-Cell Tumors

Semaglutide carries an FDA black box warning based on findings in rodent studies where GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumors. Human relevance is currently unknown, but semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Other Important Precautions

Pancreatitis: Rare but reported. Discontinue if acute pancreatitis is suspected.
Diabetic retinopathy: Rapid improvement in blood sugar can temporarily worsen diabetic retinopathy in some patients—discuss with your ophthalmologist.
Gastroparesis: Not recommended for patients with severe gastric motility disorders.
Pregnancy: Discontinue at least 2 months before a planned pregnancy. Not recommended during breastfeeding.
Drug interactions: Slowed gastric emptying can affect the absorption of oral medications taken concurrently—particularly oral contraceptives and antibiotics.

Semaglutide vs. Tirzepatide: SURMOUNT-5 Head-to-Head Results

For years, semaglutide and tirzepatide were compared only indirectly. The 2025 SURMOUNT-5 trial published in the New England Journal of Medicine provided the first direct head-to-head comparison in 751 adults with obesity without diabetes. Participants received either the maximum tolerated dose of tirzepatide (10 or 15 mg/week) or the maximum tolerated dose of semaglutide (1.7 or 2.4 mg/week) for 72 weeks.

Key results:

Mean weight loss: −20.2% with tirzepatide vs. −13.7% with semaglutide
Tirzepatide produced 47% greater weight loss than semaglutide over 72 weeks
Achieving ≥25% body weight loss: 31.6% on tirzepatide vs. 16.1% on semaglutide
GI-related treatment discontinuation: 5.6% with semaglutide vs. 2.7% with tirzepatide

Tirzepatide's advantage stems from its dual mechanism—it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, compared to semaglutide's single GLP-1 target. GIP appears to enhance the weight loss effects of GLP-1 activation through complementary pathways.

That said, semaglutide remains a highly effective option. Its cardiovascular benefit data is more robust (SELECT trial), it has a longer track record in real-world use, compounding options may make it more accessible in some markets, and the oral Wegovy pill introduces a new convenience advantage. For many patients, semaglutide is a first-line choice—and for those who need more, tirzepatide or newer agents like retatrutide represent the next step.

Who Is a Candidate for Semaglutide?

Wegovy (semaglutide for weight management) is FDA-approved for:

Adults with a BMI ≥30 kg/m² (obesity), or
Adults with a BMI ≥27 kg/m² (overweight) and at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea

Ozempic is prescribed for adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control. It's also indicated for adults with type 2 diabetes and established cardiovascular disease to reduce the risk of major cardiovascular events.

Semaglutide is not appropriate for patients who are pregnant, planning pregnancy within 2 months, have a personal or family history of MTC or MEN 2, or have a known hypersensitivity to semaglutide or any component of the formulation.

The Bottom Line

Semaglutide is one of the most clinically significant pharmacological advances in metabolic medicine in decades. Its combination of meaningful weight loss, blood sugar control, and now demonstrated cardiovascular risk reduction sets it apart from nearly every other drug in its class. The addition of an oral formulation in 2026 removes a significant barrier for patients reluctant to self-inject.

For those navigating obesity, type 2 diabetes, or elevated cardiovascular risk, semaglutide represents a proven, science-backed option with a track record across millions of real-world patients. While newer dual and triple agonists like tirzepatide and retatrutide are pushing efficacy higher, semaglutide remains the gold standard against which all successors are measured.

This article is for educational purposes only. Semaglutide is a prescription medication. Always consult a licensed healthcare provider before starting, stopping, or adjusting any medication.